hCG Explained: What It Is and How It’s Regulated in Australia
Published 19 September 2026
hCG Explained: What It Is and How It’s Regulated in Australia
Updated September 2026
Human chorionic gonadotropin (hCG) is a naturally occurring hormone with established medical uses and a substantially different regulatory position from many of the unapproved peptides discussed online. In Australia, specific hCG medicines are included in the Australian Register of Therapeutic Goods (ARTG), meaning those particular products have been evaluated for their approved uses. However, approval applies to the specific medicine, formulation and indications described in the relevant regulatory documentation; it does not mean that every possible use of hCG is TGA-approved. (Therapeutic Goods Administration, 2024; Therapeutic Goods Administration, 2026).
This article explains what hCG is, how approved hCG medicines are used in Australia, the distinction between approved and off-label use, and how compounded medicines fit within the Australian regulatory framework. It is provided for general educational purposes only. (Therapeutic Goods Administration, 2026; Ahpra, 2026).
What is hCG?
Human chorionic gonadotropin is a naturally occurring glycoprotein hormone produced during pregnancy. Pharmaceutical preparations of hCG and recombinant forms of its active hormone component have been developed for medical use because hCG can act through the luteinising hormone receptor and influence reproductive processes. (Therapeutic Goods Administration, 2026).
In clinical medicine, hCG has an established role in reproductive medicine. For example, the Australian Product Information for Ovidrel states that choriogonadotropin alfa is used to trigger final follicular maturation and luteinisation following stimulation of follicular development in women undergoing assisted reproductive techniques, and to trigger ovulation and luteinisation in appropriately selected anovulatory or oligo-ovulatory women following stimulation. (Therapeutic Goods Administration, 2026).
Is hCG approved in Australia?
Yes — specific hCG medicines are included in the ARTG. For example, Ovidrel (choriogonadotropin alfa) has an active ARTG medicine entry under ARTG ID 96037, while an additional Ovidrel pre-filled pen presentation is listed under ARTG ID 170446. These are prescription medicines with defined regulatory information and approved indications. (Therapeutic Goods Administration, ARTG 96037; Therapeutic Goods Administration, ARTG 170446).
This is an important distinction between hCG and an unapproved peptide. An ARTG entry means the particular therapeutic good has been assessed within the TGA’s regulatory framework for the purposes for which it is registered. The ARTG records information including the product, formulation, sponsor and regulatory status. (Therapeutic Goods Administration, 2024).
However, the existence of an ARTG-registered hCG medicine does not mean that hCG is approved for every possible clinical purpose. Therapeutic goods are registered with specific product information and indications, and the approved use of a particular medicine should be distinguished from other uses that may fall outside that approved information. (Therapeutic Goods Administration, 2024; Ahpra, 2026).
What are the approved uses of hCG?
One established use of recombinant hCG in Australia is in assisted reproductive medicine. Ovidrel is indicated for women undergoing controlled ovarian stimulation before assisted reproductive techniques, where it is administered to trigger final follicular maturation and luteinisation following stimulation of follicular growth. (Therapeutic Goods Administration, 2026).
Ovidrel is also indicated for appropriately selected anovulatory or oligo-ovulatory women after stimulation of follicular growth, where it is used to trigger ovulation and luteinisation. These indications are product-specific and should not be generalised to every formulation or use of hCG. (Therapeutic Goods Administration, 2026).
Australian regulatory records also document the longstanding use of gonadotrophin medicines in reproductive care, including historical scheduling material and assessment information for related fertility medicines used with hCG. These sources provide clinical and regulatory context but do not turn a related gonadotrophin product into an hCG medicine or expand Ovidrel’s approved indications. (Therapeutic Goods Administration, 2006; Therapeutic Goods Administration, 2021).
Why does the indication matter?
An important principle in Australian medicines regulation is that approval is not simply a statement about the active ingredient in isolation. The regulatory status relates to the particular therapeutic good, including its formulation, quality, manufacturing information and approved conditions of use. (Therapeutic Goods Administration, 2024).
For this reason, saying that “hCG is TGA-approved” without qualification can be misleading. A more accurate description is that specific hCG-containing medicines are included in the ARTG for specific approved uses. Other uses of hCG may involve different regulatory and professional considerations. (Therapeutic Goods Administration, 2024; Therapeutic Goods Administration, 2026).
What is off-label use?
A medicine is generally described as being used off-label when a registered medicine is used in a way that differs from the approved product information, such as for a different indication, patient population, dose, route or duration. Off-label prescribing is distinct from using an unapproved medicine because the underlying medicine itself is already included in the ARTG. (Ahpra, 2026).
Ahpra’s guidance explains that prescribing medicines off-label requires appropriate clinical reasoning and consideration of the evidence. Practitioners should explain the off-label nature of the use, discuss relevant benefits, risks and alternatives, document their clinical reasoning and consent, and establish appropriate monitoring and review arrangements. (Ahpra, 2026; Ahpra case studies, 2026).
Therefore, off-label does not mean “unapproved medicine”. The medicine may be ARTG-registered, while the particular use being considered is outside the approved indication or product information. (Ahpra, 2026; Therapeutic Goods Administration, 2024).
What is compounded hCG?
Compounding is a separate regulatory concept again. A compounded medicine is prepared for an individual patient rather than being an ARTG-registered commercial product in the same way as a standard registered medicine. The TGA states that it does not evaluate the safety, quality or efficacy of compounded medicines before they are supplied to a patient. (Therapeutic Goods Administration, 2026).
Australian professional guidance states that a compounded medicine should generally only be prescribed where there is a clinical indication and an appropriate commercial product is unavailable or unsuitable, and where compounding is not prohibited by law. Practitioners and pharmacists also have individual legal and professional responsibilities when compounded medicines are prescribed and supplied. (Ahpra, 2024).
This creates an important distinction: an approved commercial hCG medicine and a compounded hCG preparation are not automatically the same regulatory product. The fact that an active ingredient has an approved commercial medicine does not, by itself, make every compounded formulation containing that ingredient an ARTG-registered medicine. (Therapeutic Goods Administration, 2026; Ahpra, 2024).
Why does individual assessment matter?
Whether a particular medicine is appropriate for an individual is a clinical decision. Ahpra’s guidance on off-label, unapproved and compounded medicines emphasises that practitioners should consider the individual patient’s circumstances, available evidence, risks and alternatives before prescribing. (Ahpra, 2026).
For compounded medicines in particular, professional guidance states that practitioners should have a clear clinical reason for using a compounded preparation and should consider whether an appropriate approved commercial product is available or suitable. Patients should also understand when they are receiving a compounded medicine and the relevant implications. (Ahpra, 2024; Ahpra, 2026).
A person’s interest in hCG, or information they may have encountered online, does not itself establish that a particular hCG product, indication, dose or formulation is clinically appropriate. Those decisions remain matters for the responsible healthcare practitioner acting within their professional scope and applicable Australian requirements. (Ahpra, 2026).
hCG: approved, off-label and compounded use
| Situation | Regulatory position |
|---|---|
| ARTG-registered hCG medicine used for its approved indication | The particular medicine is an approved therapeutic good for its registered indications. (Therapeutic Goods Administration, 2026). |
| ARTG-registered hCG medicine used outside its approved indication | This may constitute off-label use. The medicine remains ARTG-registered, but the particular use is outside its approved indication. (Ahpra, 2026). |
| Compounded hCG preparation | A compounded preparation is distinct from an ARTG-registered commercial product and is subject to the applicable compounding requirements. (Therapeutic Goods Administration, 2026; Ahpra, 2024). |
| An unapproved hCG product | If a particular therapeutic good is not included in the ARTG and is not otherwise exempt, it is an unapproved therapeutic good and cannot simply be treated as an ARTG-approved medicine. (Therapeutic Goods Administration, 2026). |
Frequently Asked Questions
Is hCG approved in Australia?
Yes, specific hCG medicines are ARTG-registered. For example, Ovidrel (choriogonadotropin alfa) is listed in the ARTG as a prescription medicine with defined indications. This does not mean every hCG product or every possible use of hCG is approved. (Therapeutic Goods Administration, 2026; Therapeutic Goods Administration, 2026).
Is all hCG use approved by the TGA?
No. The regulatory status depends on the particular therapeutic good and its approved conditions of use. A registered hCG medicine may have specific approved indications, while another use may be considered off-label or involve a compounded preparation. (Therapeutic Goods Administration, 2024; Ahpra, 2026).
Is off-label hCG the same as an unapproved medicine?
No. Off-label use generally involves an ARTG-registered medicine being used outside its approved product information. An unapproved medicine, by contrast, is not included in the ARTG unless a relevant exemption or other regulatory pathway applies. (Ahpra, 2026; Therapeutic Goods Administration, 2026).
Does compounding make hCG TGA-approved?
No. A compounded preparation is not automatically an ARTG-registered medicine simply because its active ingredient is present in an approved commercial product. Compounding is governed by its own regulatory and professional requirements. (Therapeutic Goods Administration, 2026; Ahpra, 2024).
Why is hCG different from many other peptides discussed online?
hCG has a long-established medical history and there are specific hCG-containing medicines included in the ARTG. This is materially different from a peptide that has not been included in the ARTG as an approved therapeutic good. (Therapeutic Goods Administration, 2026; Therapeutic Goods Administration, 2026).
Does an ARTG listing mean a medicine is appropriate for everyone?
No. ARTG registration establishes the regulatory status of the particular therapeutic good and its approved uses; it does not mean that the medicine is appropriate for every individual. Clinical prescribing still requires assessment of the particular patient and the relevant indication. (Therapeutic Goods Administration, 2024; Ahpra, 2026).
Key takeaway
hCG occupies a different regulatory position from many unapproved peptides discussed online. Specific hCG medicines, including recombinant choriogonadotropin alfa products such as Ovidrel, are included in the ARTG and have defined approved indications in Australia. (Therapeutic Goods Administration, 2026; Therapeutic Goods Administration, 2026).
The important distinction is that an approved hCG medicine, an off-label use of an approved hCG medicine, and a compounded hCG preparation are not necessarily the same regulatory situation. Understanding which product is being used, for what indication and under what regulatory framework is essential when discussing hCG in Australia. (Therapeutic Goods Administration, 2024; Ahpra, 2024; Ahpra, 2026).
Educational disclaimer
This article is provided for general educational and informational purposes only. It is not medical advice and does not represent that hCG, or any particular hCG product or formulation, is appropriate, safe or effective for a particular individual or purpose. Approved indications and regulatory requirements apply to specific therapeutic goods and may change over time. (Therapeutic Goods Administration, 2024; Therapeutic Goods Administration, 2026).
Clinical decisions concerning medicines, including decisions about approved, off-label or compounded medicines, are matters for appropriately qualified and registered healthcare practitioners acting within their professional scope and applicable Australian requirements. Ahpra guidance emphasises evidence-based prescribing, informed consent, documentation and appropriate monitoring when medicines are used off-label or compounded medicines are considered. (Ahpra, 2026; Ahpra, 2024).
GL Vitality Drips operates as a consultation coordination and administrative support service and does not diagnose, treat or prescribe. Clinical decisions are made independently by appropriately qualified and registered healthcare practitioners following individual assessment.
References
- Australian Health Practitioner Regulation Agency (Ahpra) (2024). Joint statement on professional responsibilities for prescribing and dispensing medicines.
- Australian Health Practitioner Regulation Agency (Ahpra) (2026). Prescribing off-label, unapproved or compounded medicines.
- Australian Health Practitioner Regulation Agency (Ahpra) (2026). Meeting your professional obligations when prescribing off-label, unapproved or compounded medicines — Case studies.
- Therapeutic Goods Administration (2006). National Drugs and Poisons Schedule Committee Record of Reasons — Meeting 47.
- Therapeutic Goods Administration (2021). Ovaleap — Australian Public Assessment Report for follitropin alfa.
- Therapeutic Goods Administration (2024). About the Australian Register of Therapeutic Goods (ARTG).
- Therapeutic Goods Administration (2026). Manufacturing, supplying and advertising compounded medicines lawfully.
- Therapeutic Goods Administration (2026). OVIDREL choriogonadotropin alfa 250 microgram/0.5 mL pre-filled syringe — ARTG 96037.
- Therapeutic Goods Administration (2026). OVIDREL choriogonadotropin alfa 250 microgram/0.5 mL pre-filled pen — ARTG 170446.
- Therapeutic Goods Administration (2026). Searching the Australian Register of Therapeutic Goods.
Related reading
A note on this article
This article is general educational information only. It is not medical advice, and it is not a representation that any substance is safe, effective or approved for any purpose. It is not intended to promote the use, purchase or supply of any therapeutic good. Substances that have not been evaluated by the TGA carry unknown risks, including possible side effects, interactions with other medicines and unknown long-term safety.
GL Vitality Drips is a consultation coordination and administrative support service. We do not diagnose, treat, or prescribe, and GL Vitality Drips does not provide, supply, or grant access to any therapeutic good. Any consultation, assessment or pharmacy dispensing is arranged solely by independent, registered healthcare practitioners and licensed Australian pharmacies, subject to their own eligibility criteria. Not all individuals will be suitable candidates, and no outcome is guaranteed.
